Table 1

Baseline patient demographic and clinical characteristics (intention-to-treat group)

CDPI (n=183)TIS (n=191)Total (n=374)
Mean age (SD), years21.3 (9.72)20.9 (9.30)21.1 (9.49)
Range6–556–566–56
Male (%)103 (56.3)101 (52.9)204 (54.5)
Female (%)80 (43.7)90 (47.1)170 (45.5)
Mean weight (SD), kg49.37 (15.501)48.69 (15.779)49.02 (15.626)
 6–12 years24.35 (6.096)28.42 (10.907)26.53 (9.174)
 13–17 years44.63 (9.194)41.33 (8.990)42.89 (9.185)
 18+ yearsNot availableNot availableNot available
Mean BMI (SD), kg/m218.67 (3.396)18.46 (3.584)18.56 (3.490)
 6–12 years14.42 (1.786)14.99 (3.814)14.73 (3.041)
 13–17 years17.42 (2.576)16.80 (2.465)17.09 (2.522)
 18+ yearsNot availableNot availableNot available
Percentage of patients with FEV1% predicted <50%44.849.747.3 (no difference, p=0.375)
Mean FEV1% predicted (SD)49.14 (14.895)50.80 (6.336)49.78 (11.980)
 6–12 years54.15 (15.637)52.14 (14.305)53.07 (14.855)
 13–17 years51.26 (15.115)52.69 (14.696)52.02 (14.825)
 18+ yearsN/AN/AN/A
Mean time since diagnosis (SD), years17.1 (8.77)17.5 (8.71)17.3 (8.73)
  • BMI, body mass index; CDPI, Colobreathe dry powder for inhalation; FEV1, forced expiratory volume in 1 s; TIS, tobramycin inhaler solution.